1. |
Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma[J]. Cancer Chemother Pharmacol, 2008, 62(2):293-298.
|
2. |
Trinh VA. Current management of metastatic melanoma[J]. Am J Health Syst Pharm, 2008, 65(24 Suppl 9):S3-S8.
|
3. |
蒋骑, 黄俊辉. 沙利度胺联合DVP化疗方案治疗恶性黑色素瘤28 例[J]. 现代肿瘤医学, 2009, 17(1):110-111.
|
4. |
张云, 殷忠美, 王守峰, 等. 上牙龈多发恶性黑色素瘤一例报道[J]. 中国肿瘤外科杂志, 2012, 4(5):309-310.
|
5. |
Chmielowski B. Ipilimumab:a First-in-Class T-Cell potentiator for metastatic melanoma[J]. J Skin Cancer, 2013(2013):423829.
|
6. |
李丹丹, 刘磊. Ipilimumab在恶性黑色素瘤免疫治疗中的进展[J]. 华西医学, 2012, 27(4):135-139.
|
7. |
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma[J]. N Engl J Med, 2013, 369(2): 122-133.
|
8. |
练炼, 马德亮, 陶敏. 恶性黑色素瘤的分子靶向治疗进展[J]. 实用肿瘤杂志, 2010, 25(2):109-112.
|
9. |
Hwu WJ, Krown SE, Panageas KS, et al. Temozolomide plus Thalidomide in patients with advanced melanoma:results of a dose-finding trial[J]. J Clin Oncol, 2002, 20(11):2610-2615.
|
10. |
于燕霞, 石远凯. 沙利度胺在恶性肿瘤治疗中的应用[J]. 癌症进展, 2005, 3(4):353-359.
|